Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abacavir/lamivudine/lopinavir/ritonavir - Cipla/Drugs for Neglected Diseases Initiative

Next Previous
Drug Profile

Abacavir/lamivudine/lopinavir/ritonavir - Cipla/Drugs for Neglected Diseases Initiative

Alternative Names: 4-in-1 fixed combination ARV therapy - Cipla/Drugs for Neglected Diseases Initiative Foundation; 4-in-1 paediatric antiretroviral drug combination - Cipla/Drugs for Neglected Diseases Initiative Foundation; Abacavir/lamivudine/lopinavir/ritonavir; Lopinavir/r/lamivudine/abacavir; Lopinavir/ritonavir/3TC/ABC; Lopinavir/ritonavir/3TC/AZT; Lopinavir/ritonavir/lamivudine/abacavir; Lopinavir/ritonavir/lamivudine/zidovudine; LPV/r/ABC/3TC - Cipla/Drugs for Neglected Diseases Initiative Foundation; LPV/r/AZT/3TC - Cipla/Drugs for Neglected Diseases Initiative Foundation; Quadruple fixed combination HIV therapy - Cipla/Drugs for Neglected Diseases Initiative Foundation

Latest Information Update: 06 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cipla
  • Class Amides; Antiretrovirals; Carbamates; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Pyrimidine nucleosides; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors; HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors; PRINS expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV infections

Most Recent Events

  • 03 Mar 2024 Pharmacokinetics data from a phase I/II trial in HIV infections presented at the 31th Conference on Retroviruses and Opportunistic Infections (CROI-2024)
  • 19 Feb 2023 Pharmacokinetics and adverse events data from a phase I/II trial in HIV infections presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI-2023)
  • 02 Aug 2019 Drugs for Neglected Diseases announces intention to submit application for registration to the regulatory body for HIV infections in 2019

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top